院前呼气末二氧化碳可预测创伤患者死亡与大量输血:东部创伤外科协会多中心试验
本研究为24中心回顾性多中心试验,纳入1324例插管创伤患者,评估院前ETCO2对死亡和大量输血(6小时内>10 U血或6小时内死亡且至少输1 U血)的预测价值。预测大量输血时,院前最低ETCO2的AUROC为0.69,收缩压0.75、休克指数0.74。在血压正常患者中,最低院前ETCO2预测死亡(AUROC 0.66)优于收缩压(0.52)和休克指数(0.56)(p<0.001),预测大量输血AUROC为0.75。ETCO2预测大量输血的截断值为26 mm Hg,阳性预测值16.1%,阴性预测值98.1%。
要点
- 血压正常患者中,最低院前ETCO2预测死亡AUROC 0.66,优于收缩压0.52和休克指数0.56(p<0.001),对隐匿性休克有提示价值。
- ETCO2预测大量输血截断值26 mm Hg,阳性预测值16.1%,阴性预测值98.1%,低值提示需备血但阳性预测值有限。
- 大量输血定义为6小时内输注>10 U血或6小时内死亡且至少输注1 U血。
适用人群与场景
- 纳入24个中心的插管创伤患者,共1324例;收集院前、急诊科和院内数值。
诊断标准与关键阈值
- 大量输血定义:6小时内输注>10 U血,或6小时内死亡且至少输注1 U血。
- ETCO2预测大量输血的截断值为26 mm Hg。
- 原文未提及其他诊断评分界值或启动/停止阈值。
处置流程与药物剂量
- 原文未提及具体处置流程或药物剂量;研究仅评估院前ETCO2对死亡和大量输血的预测价值。
红旗征与不能漏的情况
- 院前ETCO2低至26 mm Hg及以下提示大量输血风险,但阳性预测值仅16.1%,需结合其他指标;阴性预测值98.1%有助于排除。
- 血压正常但院前最低ETCO2偏低者死亡风险仍较高,不能因血压正常而放松警惕(隐匿性休克)。
研究设计与关键结果
- 回顾性多中心试验,24个中心,1324例插管创伤患者;评估院前ETCO2对死亡和大量输血的预测。
- 预测大量输血:院前最低ETCO2 AUROC 0.69(0.64-0.75),收缩压0.75(0.70-0.81),休克指数0.74(0.68-0.79)。
- 血压正常患者中,最低院前ETCO2预测死亡AUROC 0.66(0.61-0.71),优于收缩压0.52(0.47-0.58)和休克指数0.56(0.50-0.62),p<0.001;预测大量输血AUROC 0.75(0.65-0.84),收缩压0.63(0.54-0.74),休克指数0.64(0.54-0.75)。
- ETCO2预测大量输血截断值26 mm Hg,阳性预测值16.1%,阴性预测值98.1%。
证据类型、等级与局限
- 证据类型:回顾性多中心诊断性试验;原文标注证据等级为Diagnostic test, level III。
- 局限:回顾性设计,原文未提及其他局限。
对床旁实践的改变
- 对插管创伤患者,可将院前ETCO2作为死亡风险评估的辅助指标,其预测死亡优于收缩压和休克指数。
- 血压正常者中,低院前ETCO2提示隐匿性休克和大量输血风险,不应仅凭血压正常而降低警惕。
- ETCO2≤26 mm Hg提示大量输血风险但阳性预测值低(16.1%),不宜单独作为启动大量输血的决策依据;阴性预测值高(98.1%),低值排除价值较好。
指南或共识出处
- 原文未提及具体指南或共识名称;研究来自东部创伤外科协会(Eastern Association for Surgery of Trauma)多中心试验。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Prehospital identification of the injured patient likely to require emergent care remains a challenge. End-tidal carbon dioxide (ETCO2) has been used in the prehospital setting to monitor respiratory physiology and confirmation of endotracheal tube placement. Low levels of ETCO2 have been demonstrated to correlate with injury severity and mortality in a number of in-hospital studies. We hypothesized that prehospital ETCO2 values would be predictive of mortality and need for massive transfusion (MT) in intubated patients.
METHODS: This was a retrospective multicenter trial with 24 participating centers. Prehospital, emergency department, and hospital values were collected. Receiver operating characteristic curves were created and compared. Massive transfusion defined as >10 U of blood in 6 hours or death in 6 hours with at least 1 U of blood transfused.
RESULTS: A total of 1,324 patients were enrolled. ETCO2 (area under the receiver operating characteristic curve [AUROC], 0.67; confidence interval [CI], 0.63-0.71) was better in predicting mortality than shock index (SI) (AUROC, 0.55; CI, 0.50-0.60) and systolic blood pressure (SBP) (AUROC, 0.58; CI, 0.53-0.62) (p < 0.0005). Prehospital lowest ETCO2 (AUROC, 0.69; CI, 0.64-0.75), SBP (AUROC, 0.75; CI, 0.70-0.81), and SI (AUROC, 0.74; CI, 0.68-0.79) were all predictive of MT. Analysis of patients with normotension demonstrated lowest prehospital ETCO2 (AUROC, 0.66; CI, 0.61-0.71), which was more predictive of mortality than SBP (AUROC, 0.52; CI, 0.47-0.58) or SI (AUROC, 0.56; CI, 0.50-0.62) (p < 0.001). Lowest prehospital ETCO2 (AUROC, 0.75; CI, 0.65-0.84), SBP (AUROC, 0.63; CI, 0.54-0.74), and SI (AUROC, 0.64; CI, 0.54-0.75) were predictive of MT in normotensive patients. ETCO2 cutoff for MT was 26 mm Hg. The positive predictive value was 16.1%, and negative predictive value was high at 98.1%.
CONCLUSION: Prehospital ETCO2 is predictive of mortality and MT. ETCO2 outperformed traditional measures such as SBP and SI in the prediction of mortality. ETCO2 may outperform traditional measures in predicting need for transfusion in occult shock.
LEVEL OF EVIDENCE: Diagnostic test, level III.
参考来源
- Campion EM, Cralley A, Sauaia A, et al. Prehospital end-tidal carbon dioxide is predictive of death and massive transfusion in injured patients: An Eastern Association for Surgery of Trauma multicenter trial. J Trauma Acute Care Surg. 2022. PMID: 34686640. doi:10.1097/TA.0000000000003447
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。